Journal of Experimental & Clinical Cancer Research

Celebrating the 10th anniversary partnership with BMC

2018 marks the 10^th anniversary of the partnership between the Journal of Experimental & Clinical Cancer Research and BMC.

Over the past decade, the journal has established itself among some of the top Oncology titles in Journal Citation Reports. Click here to look back at some of the journal’s milestone achievements and best content from the past 10 years.

Featured Article: The perfect personalized cancer therapy: cancer vaccines against neoantigens

Personalized cancer therapy is an emerging field in oncology research since the premise of being able to specifically target a causative mutation of a tumor, whilst reducing the side-effects of normal tissue, enables this type of approach to be uniquely tailored to each patient, to help maximize the effectiveness that the therapy will have. Targeting tumor neoantigens are considered an ideal target in personalized cancer therapy.

In this review, L. Aurisicchio et al. give an overview on immune recognition of tumor cells and discuss the evidence regarding mutation-derived neoantigen cancer vaccines.

Click here to access the full article.

Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Content type: Research
| 18 September 2018

miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2)

Authors: Xi He, Si-yuan Chen, Zhao Yang, Jie Zhang, Wei Wang, Mei-yue Liu, Yi Niu, Xiao-mei Wei, Hong-min Li, Wan-ning Hu and Guo-gui Sun
Content type: Research
| 15 September 2018

LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling

Authors: Yang Cheng, Tianlu Hou, Jian Ping, Tianyang Chen and Baobing Yin
Content type: Review
| 14 September 2018

The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications

Authors: Hongmei Zheng, Yuting Zhan, Sile Liu, Junmi Lu, Jiadi Luo, Juan Feng and Songqing Fan
Content type: Research
| 14 September 2018

TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma

Authors: Xian-Yue Ren, Xin Wen, Ying-Qing Li, Jian Zhang, Qing-Mei He, Xiao-Jing Yang, Xin-Ran Tang, Ya-Qin Wang, Pan-Pan Zhang, Xiao-Zhong Chen, Bin Cheng, Jun Ma and Na Liu
Content type: Research
| 12 September 2018

LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients

Authors: Jin Zhang, Hongqing Cai, Lixin Sun, Panpan Zhan, Meng Chen, Feng Zhang, Yuliang Ran and Jinghai Wan

Most recent articles RSS

View all articles

Content type: Review
| 26 September 2011

Apoptosis in cancer: from pathogenesis to treatment

Authors: Rebecca SY Wong
Content type: Review
| 6 October 2015

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

Authors: Go J. Yoshida
Content type: Research
| 3 February 2016

HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer

Authors: Jian Yang, Xu Zhang, Yi Zhang, Dongming Zhu, Lifeng Zhang, Ye Li, Yanbo Zhu, Dechun Li and Jian Zhou
Content type: Research
| 14 September 2009

Characterization of human breast cancer epithelial cells (HBCEC) derived from long term cultured biopsies

Authors: Ralf Hass and Catharina Bertram
Content type: Research article
| 5 February 2015

Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer

Authors: Jingtao Wang, Feifei Cui, Xiao Wang, Yingming Xue, Jian Chen, Yang Yu, Huijun Lu, Meng Zhang, Huamei Tang and Zhihai Peng

Most accessed articles RSS

View all articles

Meeting reports now accepted

Journal of Experimental & Clinical Cancer Research now welcomes the submission of Meeting reports to help showcase novel developments presented at meetings and conferences.

Please click here for more information on the article types accepted by Journal of Experimental & Clinical Cancer Research.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to:

jeccreditorial@gmail.com

2017 Impact Factor

We are delighted to share with our readers that Journal of Experimental & Clinical Cancer Research has an Impact Factor of 6.217 and is currently ranked at 33 out of 222 (Q1) in the Oncology category of Journal Citation Reports (Clarivate Analytics, 2018).

We would like to extend our appreciation to all Editorial Board Members, authors and peer reviewers who have contributed to the journal and enabled this achievement.

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982. Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print. For enquiries about previous content, please contact us on:

jeccreditorial@gmail.com

Reviewer Acknowledgement

The editorial team of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal.

Click here to visit the Reviewer acknowledgements page.

Journal of Experimental & Clinical Cancer Research

Celebrating the 10th anniversary partnership with BMC

Featured Article: The perfect personalized cancer therapy: cancer vaccines against neoantigens

Aims and scope

Articles

miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2)

LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling

The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications

TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma

LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients

Apoptosis in cancer: from pathogenesis to treatment

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer

Characterization of human breast cancer epithelial cells (HBCEC) derived from long term cultured biopsies

Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer

Meeting reports now accepted

Editor-in-Chief

2017 Impact Factor

Archival content

Reviewer Acknowledgement

Follow

2017 Journal Metrics

Journal of Experimental & Clinical Cancer Research

Contact us